Table 2

Other end points of interest/metabolic intermediates change from baseline to end of study

Liraglutide 1.2 mgLiraglutide 1.8 mgPlacebo
Blood pressure (mmHg)
    SBP−6.7 ± 1.1*−5.6 ± 1.1*−1.1 ± 1.2
    DBP−2.3 ± 0.7−1.9 ± 0.7−0.8 ± 0.7
β-Cell function
    Insulin (pmol/l)6.0 ± 5.85.6 ± 5.56.8 ± 6.0
    C-peptide (pmol/l)131 ± 32*144 ± 31*51 ± 34
    Proinsulin-to-insulin ratio−0.029 ± 0.026*−0.085 ± 0.26*0.036 ± 0.029
    β-Cell function (%) (HOMA-B)27 ± 4.4*27 ± 4.2*6 ± 4.5
    Insulin resistance (HOMA-IR)−0.6 ± 0.3−0.7 ± 0.3−0.3 ± 0.3
    Proinsulin–to–C-peptide ratio−0.007 ± 0.001*−0.008 ± 0.001*−0.002 ± 0.001
    Fasting glucagon (pg/ml)−5.9 ± 2.9−6.7 ± 2.8−0.4 ± 3.0
Lipids
    Total cholesterol (mmol/l)−0.21 ± 0.9−0.20 ± 0.09−0.02 ± 0.10
    LDL cholesterol (mmol/l)−0.28 ± 0.07*−0.23 ± 0.07−0.10 ± 0.07
    VLDL cholesterol (mmol/l)0.12 ± 0.030.10 ± 0.030.11 ± 0.03
    HDL cholesterol (mmol/l)−0.03 ± 0.02−0.04 ± 0.02−0.03 ± 0.02
    Triglycerides (mmol/l)−0.38 ± 0.10*−0.32 ± 0.10−0.13 ± 0.11
    Free fatty acids (mmol/l)−0.03 ± 0.02*−0.05 ± 0.02*0.02 ± 0.02
  • Data are means ± SE, unless otherwise noted.

  • *P < 0.05 vs. placebo.